We have detected that your browser does not have Javascript turned on. This site is optimized for Javascript.
You may experience difficulties browsing certain parts of the site.
Home Search Contact Us Genzyme Websites
Choose your area of interest Patients Health Care Professionals Business Customers Investors Media Careers
Fabrazyme for the Treatment of Fabry Disease:
United States Approval, April 24, 2003 The following links and information are provided by Genzyme Corporation as a resource for information on the US approval of Fabrazyme (agalsidase beta) for the treatment of patients with Fabry disease. Product information published here applies only to health care professionals and patients in the United States. Fabrazyme is approved for use in over 27 countries including those in the European Union. On This Page Fabrazyme Overview
Other related websites Contact information
Corporate Communications
Fabrazyme Overview Fabry Disease is an inherited disorder caused by the deficiency of an enzyme called alpha-galactosidase A, or alpha-GAL. Fabrazyme is intended to provide an exogenous source of the deficient enzyme in patients with Fabry disease. Clinical manifestations of Fabry disease may include renal failure, cardiomyopathy and cerebrovascular accidents. For more, please see the | |
|
